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Abstract
Portal hypertension (PH) is a common complication and a leading cause of death in patients with chronic liver diseases. PH
is underlined by structural and functional derangement of liver sinusoid vessels and its fenestrated endothelium. Because in
most clinical settings PH is accompanied by parenchymal injury, it has been difficult to determine the precise role of
microvascular perturbations in causing PH. Reasoning that Vascular Endothelial Growth Factor (VEGF) is required to
maintain functional integrity of the hepatic microcirculation, we developed a transgenic mouse system for a liver-specific-,
reversible VEGF inhibition. The system is based on conditional induction and de-induction of a VEGF decoy receptor that
sequesters VEGF and preclude signaling. VEGF blockade results in sinusoidal endothelial cells (SECs) fenestrations closure
and in accumulation and transformation of the normally quiescent hepatic stellate cells, i.e. provoking the two processes
underlying sinusoidal capillarization. Importantly, sinusoidal capillarization was sufficient to cause PH and its typical sequela,
ascites, splenomegaly and venous collateralization without inflicting parenchymal damage or fibrosis. Remarkably, these
dramatic phenotypes were fully reversed within few days from lifting-off VEGF blockade and resultant re-opening of SECs’
fenestrations. This study not only uncovered an indispensible role for VEGF in maintaining structure and function of mature
SECs, but also highlights the vasculo-centric nature of PH pathogenesis. Unprecedented ability to rescue PH and its
secondary manifestations via manipulating a single vascular factor may also be harnessed for examining the potential utility
of de-capillarization treatment modalities.
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Introduction
Different insults inflicting hepatocyte damage, such as alcohol or
acute and chronic viral infections, may eventually lead to cirrhosis
and intra-hepatic portal hypertension (PH). Anatomical changes
such as fibrotic scar and regenerative nodule formation that result
in mechanical compression of the hepatic vasculature have been
traditionally implicated as the dominant cause for increased intra-
hepatic vascular resistance, the hallmark of sinusoidal-type PH. It
is similarly acknowledged, however, that hepatic stellate cells
(HSCs) play a pivotal role in this process. A common pathway in
PH pathogenesis due to increased intra-hepatic resistance involves
activation of HSCs from a quiescent, vitamin A- storing
subendothelial cells to myofibroblast-like cells, endowed with a
contractile, proinflammatory and fibrogenic properties [1].
Together, HSC-associated anatomical changes contribute to
increased mechanical resistance to blood flow, while contractile
activity of activated HSCs might contribute to increased
hemodynamic pressure [2]. The sinusoidal endothelium is
distinguished by openings (fenestrations) that, together with
discontinuities in the basement membrane are essential for proper
permeability through this unique low resistance/low pressure
microvascular network. Accordingly, matrix deposition within the
space of Disse and closure of endothelial fenestrations –processes
that together underlie sinusoidal capillarization- impede the rapid
exchange of solutes between the sinusoidal space and hepatocytes,
causing increased resistance to portal blood flow and PH [3].
Thus, while parenchymal damage is considered to be the initial
event in PH pathogenesis, its impact on the hepatic microvascu-
lature appears to be the proximal cause of PH and its sequela.
Here we examined whether enforced sinusoidal capillarization,
not accompanied by parenchymal architectural derangement may
lead to PH. To this end, we have developed a unique transgenic
mouse model for perturbing the hepatic vasculature in a
conditional and reversible manner via manipulations of Vascular
Endothelial Growth Factor (VEGF).
VEGF, in addition to its activity as an angiogenic factor, also
thought to play multiple roles in adult vasculatures. Notably,
VEGF was shown to induce endothelial fenestration in vitro [4,5].
Likewise, VEGF blockade during development resulted in
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fenestrations [6]. Other studies have shown that fenestrated
endothelium, in general, is more vulnerable to VEGF withdrawal
than non-fenestrated endothelium [7]. The notion that ongoing
VEGF signaling might be required to maintain fenestrations in
adult SECs in vivo, however, has not been examined. Here we show
that VEGF is indeed essential to maintain SEC fenestrations and
HSC quiescence and that, correspondingly, mere blockade of
endogenous VEGF is sufficient to cause sinusoidal capillarization
which, in turn, leads to PH and its sequela, including ascites,
splenomegaly and the development of venuous collateral circula-
tion. Thus, the study highlights the vasculo-centric nature of PH
causation and provides a convenient experimental platform to
explore PH development without the confounding factors
associated with parenchymal damage and independently of its
different etiologies.
While rescuing PH and its sequela remains a prime clinical goal,
recent animal and clinical works have provided only limited
evidence showing that targeting endothelial dysfunction (e.g. by
statins) can decrease intra-hepatic vascular resistance of liver
vasculature in the cirrhotic liver, reduce portal pressure and result
in improved liver function [8].
Here we show that re-opening of SEC fenestrations via
restoration of VEGF function fully reverses PH and its secondary
manifestations. These finding suggest the deranged sinusoidal
network as a possible therapeutic target and attempted de-
capillarization as a possible treatment modality.
Materials and Methods
Transgenic mice and conditional modulations of VEGF
signaling
All animal procedures were approved by the animal care and
use committee of the Hebrew University, Approval #
MD11904-2 entitled: ‘‘Regulation and role of sFlt in physiology
and pathophysiology’’. A bi-transgenic system for organ specific-,
tetracycline-regulated transgene expression was used. Liver-
specific induction was obtained by using a driver line in which
tTA expression is driven by a C/EBPb (CCAAT/enhancer
binding protein b) promoter (also known as liver-activator
protein or PLAP; [9]). The responder tet-soluble VEGF-R1
transgenic line encodes a tetracycline-inducible protein com-
posed of an IgG1-Fc tail fused to the extracellular domain of
VEGF-R1 (corresponding to amino acid residues 1 to 631 of
human VEGF-R1 containing the ligand binding domain but
lacking the trans-membrane and cytoplasmic domains). Induc-
tion of soluble VEGF-R1 (sVEGF-R1) in double-transgenic mice
by tetracycline withdrawal and its shut-off by tetracycline
addition (0.5mg/ml tetracycline and 3% sucrose in the drinking
water) were carried-out as previously described [10]. Levels of
circulating sVEGF-R1 were determined using a soluble VEGF-
R1 ELISA kit (human VEGF R1 Quantikine kits DVR100,
R&D systems).
RNA analysis and in situ hybridization
Northern blotting of whole organ RNA was performed as
previously described [11]. hVEGF-R1 probe was generated by
digesting the expression vector with HindIII + SacI (1.2kb
fragment).
Histochemistry and Immunohistochemistry
5 um paraffin sections were used for light microscopy;
trichrome stain was performed according to Masson Goldner.
For vWF (factor VIII) immunestaining – factor VIII rabbit anti-
human (DAKO 1:200) was used.
Western blot
a-Smooth muscle actin (aSMA) - Whole liver protein extracts
were prepared. Blots were incubated with anti-SMA (DAKO, cat
no. M0851) mouse monoclonal antibody (1:2000).
Transmission electron microscopy
For EM studies, anesthesized mice were perfusion-fixed using a
solution of cold 2.5% glutaraldehyde in PBS, post-fixed in
osmium tetroxide, block-stained using uranyl acetate, dehydrated
through ascending concentrations of ethanol, and embedded in
epoxy resin [12]. Ultrathin sections were obtained at 90 nm,
counterstained with lead citrate and viewed on a Philips EM-300
microscope.
Ultrasonography
Abdominal ultrasound was performed on anesthetized mice
(100 ml of 17% ketamine, 3% xylazine in 0.9% NaCl, intra-
peritoneal) with a L12-15 MHz linear transducer on ATL HDI
5000 (Philips) machine for the presence of ascites.
Results
A transgenic system for conditional and reversible
suppression of VEGF signaling in the adult liver
In light of evidence that VEGF is constitutively expressed in the
adult liver and continuously transmitting VEGF-induced signals
[13], we reasoned that VEGF might play a maintenance role in
the hepatic circulation. To determine this, we developed a
transgenic system allowing for conditional suppression of endog-
enous VEGF signaling, specifically in the adult liver. The system is
based on conditional induction of a secreted soluble VEGF decoy
receptor 1 (sVEGF-R1) that sequesters VEGF and precludes its
signaling [10]. Briefly, a transgenic line harboring a sVEGF-R1-
encoding transgene driven by a tetracycline-responsive promoter
(the ‘responder’ line) was mated with a transgenic line harboring a
tetracycline-regulated transactivator protein (tTA) driven by the
liver-specific C/EBPb/PLAP promoter [9] (the ‘driver’ line)
(Fig. 1). Double transgenic mice were selected for VEGF
modulations, whereas littermates that inherited only one of the
two transgenes served as controls. The onset of sVEGF-R1
activation in double transgenic animals and the duration of its
expression were tightly controlled by including or omitting
tetracycline from the drinking water (‘off’ and ‘on’ modes,
respectively), which also allowed to restore VEGF function at
will. sVEGF-R1 expression was induced in adult mice (over 6
weeks of age) for the indicated time.
A successful ‘on’ switching of sVEGF-R1 was secured by
induction of transgenic sVEGF-R1 mRNA in the liver but not in
any other organ (Fig. 1) and by detecting the encoded protein in
the liver and circulation of double transgenics, mounting to
average of 87.4 ng/ml of circulating sVEGF-R1 compared to
undetectable levels in control mice. Noteworthy, although
sVEGF-R1 produced by the liver was also accessible to the
circulation, no phenotype was detected in any organ besides the
liver. Conversely, when the soluble VEGF receptor was induced
in the heart (using driver lines harboring the cardiac-specific
promoter) clear vascular phenotypes were detected exclusively in
the heart but not in the liver [10]. These findings indicated that
the system is indeed suitable for blocking VEGF signaling in a
tissue-specific manner.
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tions of liver sinusoidal vessels.
High resolution scanning electron microscopy (SEM) was used
to reveal ultra-structural changes in SECs subjected to VEGF
blockade. Control mice exhibited a typical SEC phenotype
distinguished by extensive clusters of fenestrations occupying
more than 40% of the endothelial surface area [14]. In contrast,
mice subjected to VEGF blockade for 4 weeks exhibited a
remarkable 5-fold reduction in fenestration, now occupying only
8.5% of the total surface area (Fig. 2). These results indicated that
ongoing VEGF signaling is required for maintaining SEC
fenestration and that a loss of VEGF function is sufficient to
cause their closure.
VEGF blockade leads to activation and transformation of
hepatic stellate cells (HSCs)
HSCs are known to undergo multiple changes in associating
with PH developing on backgrounds of viral- and alcoholic
hepatitis [1]. We therefore determined, whether similar HSC
changes may take place downstream of VEGF blockade. Results
Figure 1. A bi-transgenic system for conditional and reversible suppression of VEGF signaling in the liver. (a) A schematic
representation of the driver and responder transgenes used in the bi-transgenic system (b) Northern blot analysis of hepatic and renal RNA with a
probe specific for transgenic (human) VEGF-R1. The term ‘‘off’’ indicates control littermates; ‘‘on’’ indicates that sVEGF-R1 expression was induced for
1 month in two transgenic animals. Note the tissue specific expression of the transgene.
doi:10.1371/journal.pone.0021478.g001
Figure 2. sVEGF-R1 expression in the adult liver causes closure of sinusoidal fenestrations. (a) Scanning electron microscopy of sinusoids
in control (‘off’) showing fenestrations arranged in sieve plates (white arrows) and loss of fenestration following one month of switch ‘on’ (sVEGF-R1
expression). RBC=Red Blood Cell (b) Quantification of the percent of fenestrations’ surface area in the sinusoids. sinusoidal area. ‘off’240.5%,
‘on’28.5%.
doi:10.1371/journal.pone.0021478.g002
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activation and transformation of HSCs. Indicative of induced
HSC accumulation, there was a marked increase in the number of
HSCs occupying the peri-sinusoidal space, quantified as a nearly
8-fold increase in the surface area covered by HSCs (Figs. 3A and
C). Indicative of HSC transformation were the following
observations: I. An ultrastructural change from a lipid-storing cell
to a cell devoid of lipid droplets with a myofibroblistic-like cell
morphology (Fig. 1A). II. Upregulated expression of a-smooth
muscle actin (aSMA) which is normally expressed only by the
smooth muscle cells of the larger blood vessels (Fig. 3D). III.
Accumulation of perisinusoidal extracellular matrix, shown here
by a specific staining for collagen, known to be mainly produced
by activated-fibrogenic HSCs (Fig. 3E). Noteworthy, all of the
above changes typify HSC changes encountered during the
clinical course of PH and considered to be critical for its
pathogenesis.
Inhibition of VEGF in the liver causes sinusoidal
capillarization
Overall, the data indicated that loss of VEGF function results in
sinusoidal capillarization, i.e. the combined loss of SEC fenestra-
tions and deposition of basement membrane by activated HSC
Figure 3. sVEGF-R1 expression in the adult liver causes activation of HSCs. (a) Scanning electron microscopy of sinusoids in ‘off’ (a control
littermate) vs. switch ‘on’ liver for one month showing prominent HSCs surrounding sinusoids (arrows) (b) Scanning electron microscopy showing
transformation of HSCs from lipid droplets (L) containing cells (‘off’) to myofibroblasts like cells (arrows). (c) Quantification of the surface area of HSCs.
‘off’-5.8%, ‘on’ (sVEGF-R1 expression for one month)-43.7%. (d) Western blot analysis with anti a-smooth muscle actin antibody performed on liver
extracts (e) Goldner staining for collagen fibers (green) indicating perisinusoidal accumulation of extra-cellular matrix.
doi:10.1371/journal.pone.0021478.g003
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marked changes in the repertoire of endothelial-expressed genes,
notably acquisition of von-Willebrand factor (vWF) expression, a
protein not normally expressed by SECs and upregulated during
liver damage [15,16,17] As shown in fig. 4, sinusoidal capillariza-
tion induced by VEGF blockade was also manifested by sinusoidal
expression of vWF. Thus, ongoing VEGF signaling appears
essential for maintaining the differentiated state of liver sinusoids.
Sinusoidal capillarization was not associated with any detectable
parenchymal damage or bridging fibrosis, as evidenced by the
normal morphology of hepatocytes and by failure to detect a
regenerative liver response, bile duct pathology (Fig. 4 C), as well
as hepatocyte cell death (not shown).
VEGF inhibition culminates in portal hypertension and its
typical complications
Next, we wished to determine whether sinusoidal capillarization
caused by VEGF withdrawal might also produce all the sequela of
PH despite the otherwise normal liver morphology [2,18].To this
end, we examined mice at one month after the onset of sVEGF-R1
induction, focusing on extra-hepatic phenotypes. The develop-
ment of prominent ascites was clearly evident by abdominal
swelling (Fig. 5A) and corroborated by ultrasonography (Fig. 5B).
Splenomegaly was evident by a twofold enlargement and
congestion of the spleen (Fig. 5C). A later compensatory response
to PH often observed in the clinical setting, namely the formation
of mesenteric venous collaterals, was also evident (not shown).
Thus, the liver pathology induced by VEGF inhibition fully
reproduces the typical clinical sequela of PH.
Portal hypertension is reversible upon VEGF reactivation
In light of current debate to what extent can PH-associated
fibrosis and secondary complication be reversed upon terminating
the initial cause of injury, we wished to determine whether intra-
and extra-hepatic abnormalities in our experimental system can be
resolved upon restoring VEGF function. To this end, mice
maintained for one month in the sVEGF-R1 ‘on’ mode, i.e. at a
time point where all of the above symptoms has already been
produced (and secured by observing abdominal ascites by
ultrasonography) were transferred to the switch ‘off’ conditions
to re-gain VEGF function (‘onRoff’ mode). Noteworthy, when the
‘on’ switch was kept for a longer time, further deterioration
resulted in animal mortality.
Remarkably, all intra- and extra-hepatic phenotypes were
reversed with within 1 week of VEGF function restoration and
mice became indistinguishable from controls (due to the longer
half-life of collagen, its reduction was apparent with a few weeks
delay). This was evident as follows: SEC fenestrations re-appeared
Figure 4. Sinusoidal capillarization in sVEGF-R1 expressing livers without parenchymal damage. (a,b) Immunohistochemical staining for
vWF (Von-Willebrand Factor) on liver sections (black arrows-sinusoids, white arrows-larger blood vessels). (c) H&E staining of liver sections showing
normal appearance.
doi:10.1371/journal.pone.0021478.g004
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HSCs returned to a quiescent state as manifested in normal
abundance in the peri-sinusoidal space (Fig. 6B, compared with
the onward switch in Fig. 3C). The amount of peri-sinusoidal
collagen was reduced to an apparently close to normal level
(Fig. 6C compared to Fig. 3E). As anticipated from the re-gain of
normal sinusoidal structure and presumed return to a low
resistance state, secondary complications also disappeared includ-
ing resolution of ascites and venous collaterals and regression of
splenomegaly (not shown).
Discussion
Here we harnessed a conditional transgenic system for liver-
specific modulations of VEGF function to show that VEGF
blockade leads to closure of SEC fenestration and to activation of
peri-sinusoidal HSCs, acting in concert to induce sinusoidal
capillarization. Enforced capillarization was sufficient to produce
significant PH and its secondary complications in the absence of a
detectable parenchymal damage. These results point out that liver
fibrosis is not a mandatory requirement for PH development and
highlight the key role of vascular perturbation as the proximal
cause of PH. To our knowledge this is the first example of a PH
animal model where loss-of-function of a single protein is sufficient
to produce all hallmarks of the condition.
Initially shown to function as an angiogenic factor, VEGF was
subsequently shown to play different roles in the maintenance of
adult vasculatures. Noteworthy, VEGF is suggested to play a role
in control of systemic blood pressure, as evidenced by induced
hypertension in patients treated with the VEGF-neutralizing
antibody Bevacizumab [19]. Here, we uncovered yet another
function of VEGF, namely, a requirement for ongoing VEGF
Figure 5. Complications of portal hypertension resulting from sVEGF-R1 expression in the liver. (a) Anesthetized mice showing
abdominal distension. ‘on’-sVEGF-R1 expression for one month. (b) Abdominal ultrasonography documenting ascites after one month of sVEGF-R1
expression in the liver. L-liver lined with pink line, ascites (hypoechogenic) is marked by a yellow asterisk and a yellow line. (c) Representative spleens
taken from control (‘off’) and after one month of sVEGF-R1 expression (‘on’) in the liver. Average spleen weight is 100 mg and 193 mg in control and
transgenic mice, respectively.
doi:10.1371/journal.pone.0021478.g005
Figure 6. Liver phenotype is reversible upon relieving sVEGF-R1. One week after sVEGF-R1 shut off (onRoff) (a) Quantification of the
percent of fenestrations’ surface area in the sinusoids. ‘on’28.5%, ‘onRoff’234.4% (b)-quantification of area covered by HSCs ‘on’243.7%, ‘onRoff’
(‘on’ for one month then ‘off’ for one week)214.4% (c) Goldner staining highlighting collagen fibers in green showing reduced extracellular-matrix
deposition perisinusoidally compared to ‘on’ (fig 3E).
doi:10.1371/journal.pone.0021478.g006
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This was supported by closure of fenestrae upon inhibition of
endogenous VEGF function and their re-opening upon restoration
of VEGF function. We note that while ability of VEGF to form
new fenestrae has been previously documented [13,20], a
requirement for VEGF to maintain already formed fenestrae in
mature SECs in vivo was not previously shown, as it necessitated
the use of an on/off genetic switch system. These results are
supported by a clinical trial findings that removing VEGF from the
hepatic microvasculature in the setting of cirrhosis and portal
hypertension has deletarious effect [21].
The conditional VEGF switch system employed in this study
provides several advantages over previously used methodologies of
in vivo VEGF modulations. First, VEGF blockade takes place only
in the relevant organ, thus circumventing systemic influences. We
note in this regard that although the induced decoy receptor is a
secreted protein, its peri-cellular retention is the likely explanation
to our cumulative experience that vascular phenotypes are solely
observed in the particular organ where it is induced. Second,
unlike other methodologies of VEGF loss of function, which are
often incomplete, this system allows to attain complete VEGF
blockade. Third, the option to induce and to terminate the VEGF
blockade at any given schedule is instrumental for examining adult
phenotypes and their reversal.
The finding that VEGF is required to maintain SEC
fenestrations, in conjunction with the fact that fenestrations are
of essence for maintaining a permeable, low-resistance portal
circulation, provides an explanation to the finding that enforced
VEGF blockade results in increased resistance and portal
hypertension.
It should be pointed-out, however, that there is no evidence that
a loss of VEGF function is an etiological factor in clinical settings
of PH. Nevertheless, this experimental model might be useful for
dissecting the overall pathogenic process to its individual
contributing sub-process. This is exemplified here by singling-out
sinusoidal capillarization as the key contributor to PH develop-
ment.
Moreover, this model more closely resembles disorders
distinguished by a primary damage to the liver vasculature, such
as Budd-Chiari syndrome and Hepatic veno-occlusive disease
(hepatic sinusoidal obstruction syndrome), which are both
characterized by hepatic venous outflow obstruction at different
levels (for review see [22]), causing hepatic sinusoidal hydrostatic
pressure elevation and portal hypertension with variable stages of
parenchymal damage.
VEGF suppression in the adult liver also leads to activation of
HSCs from quiescence into a proliferative state and their
transformation from retinol-storing cells to a-smooth muscle
actin-expressing myofibroblast-like cells engaged in deposition of
extracellular matrix proteins in the space of Disse. Interestingly, a
previous study reported that upregulation of VEGF activates
HSCs [23], whereas other studies have shown that addition of
recombinant VEGF to the culture medium attenuates an increase
in a-smooth muscle actin expression in these cells, suggesting that
VEGF is indeed required for the maintenance of the differentiated
state of HSCs [24,25]. We note, however, that our study is an in
vivo study aimed at measuring maintence functions of VEGF in the
normal liver and also differ in this respect from in vivo studies
examining the effects of VEGF on HSCs in a pathological cirrhosis
model. Currently it is not known whether VEGF induces these
HSC changes directly or indirectly. An indirect effect was
suggested in an in vivo study, showing that HSC quiescence
requires both VEGF and co-culture with SECs. Therefore, VEGF
sequesetration could lead to closure of fenestration which, in turn,
is likely to result in hypoxia. Hypoxia-inducible factors other than
VEGF, such as PDGF could then activate HSCs [23,24,25,26].
The study shows that PH, as well as its secondary complications,
ascites, splenomegaly and formation of venous collaterals can be
fully reversed by VEGF reactivation. Because the natural proximal
causes of sinusoidal capillarization are unknown and unless it is
caused by a loss of VEGF function, enforcing de-capilarization for
clinical purposes requires further mechanistic insights. Neverthe-
less, our experimental system might lend itself as suitable
experimental platform in examining potential drugs with respect
to the feasibility of reversing sinusoidal capillarization and thereby
rescue PH and its complications.
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